Metronomic oral vinorelbine and lung cancer therapy during the COVID 19 pandemic: a single-center experience
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Coronavirus pandemic disease forced clinicians and health systems to radically change treatments of oncological patients, especially patients with advanced lung cancer without oncogene-drivers. During Covid19 pandemic, oncologists worldwide must choose the best strategy for these “frail” patients in order to reduce side effects and maximize the outcomes. ESMO-Guidelines during Covid19 era shows HIGH PRIORITY for “1st-line treatment including chemotherapy, chemotherapy plus Immunotherapy, Immunotherapy alone or TKIs to improve prognosis, cancer-related symptoms and QoL”. In patients without oncogene-drivers (PDL-1???50%, EGFR-mutations, B-RAF mutations, ALK and ROS-1 rearrangements), immunotherapy alone or TKIs are not suitable therapies and chemotherapy - alone or plus immunotherapy – is the treatment of choice. (…)
Lung Cancer , article en libre accès, 2019